CCM
DYN icon

Catalio Capital Management’s Dyne Therapeutics DYN Stock Holding History

Catalio Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.13M Sell
282,954
-236,761
-46% -$4.08M 1.07% 27
2025
Q4 		$10.2M Buy
+519,715
New +$9.84M 1.8% 25

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Catalio Capital Management's DYN Position: Q1 2026 in Review

Catalio Capital Management reduced its Dyne Therapeutics (DYN) stake by 46% in Q1 2026, selling an estimated $4.08M and leaving 282,954 shares worth $5.13M. The position accounts for 1.07% of the portfolio, ranked #27.

Catalio Capital Management first reported a position in DYN in Q4 2025 and has held it in 2 quarters since. The position peaked at $10.2M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Catalio Capital Management held 282,954 shares of Dyne Therapeutics worth $5.13M as of Q1 2026.
  • Catalio Capital Management sold 236,761 Dyne Therapeutics shares in Q1 2026, an estimated $4.08M.
  • Dyne Therapeutics made up 1.07% of Catalio Capital Management's portfolio in Q1 2026, its #27 holding.
  • Catalio Capital Management first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Catalio Capital Management's Dyne Therapeutics position peaked at $10.2M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.